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A B S T R A C T
Background
The Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) is a structured interview based on informant responses
that is used to assess for possible dementia. IQCODE has been used for retrospective or contemporaneous assessment of cognitive
decline. There is considerable interest in tests that may identify those at future risk of developing dementia. Assessing a population
free of dementia for the prospective development of dementia is an approach often used in studies of dementia biomarkers. In theory,
questionnaire-based assessments, such as IQCODE, could be used in a similar way, assessing for dementia that is diagnosed on a later
(delayed) assessment.
Objectives
To determine the diagnostic accuracy of IQCODE in a population free from dementia for the delayed diagnosis of dementia (test
accuracy with delayed verification study design).
Search methods
We searched these sources on 16 January 2016: ALOIS (Cochrane Dementia and Cognitive ImprovementGroup), MEDLINEOvid SP,
Embase Ovid SP, PsycINFOOvid SP, BIOSIS Previews on Thomson ReutersWeb of Science,Web of Science Core Collection (includes
Conference Proceedings Citation Index) on Thomson ReutersWeb of Science, CINAHL EBSCOhost, and LILACS BIREME.We also
searched sources specific to diagnostic test accuracy: MEDION (Universities of Maastricht and Leuven); DARE (Database of Abstracts
of Reviews of Effects, in the Cochrane Library); HTA Database (Health Technology Assessment Database, in the Cochrane Library),
and ARIF (Birmingham University). We checked reference lists of included studies and reviews, used searches of included studies in
PubMed to track related articles, and contacted research groups conducting work on IQCODE for dementia diagnosis to try to find
additional studies. We developed a sensitive search strategy; search terms were designed to cover key concepts using several different
approaches run in parallel, and included terms relating to cognitive tests, cognitive screening, and dementia. We used standardised
database subject headings, such as MeSH terms (in MEDLINE) and other standardised headings (controlled vocabulary) in other
databases, as appropriate.
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Selection criteria
We selected studies that included a population free from dementia at baseline, who were assessed with the IQCODE and subsequently
assessed for the development of dementia over time. The implication was that at the time of testing, the individual had a cognitive
problem sufficient to result in an abnormal IQCODE score (defined by the study authors), but not yet meeting dementia diagnostic
criteria.
Data collection and analysis
We screened all titles generated by the electronic database searches, and reviewed abstracts of all potentially relevant studies. Two
assessors independently checked the full papers for eligibility and extracted data. We determined quality assessment (risk of bias and
applicability) using the QUADAS-2 tool, and reported quality using the STARDdem tool.
Main results
From 85 papers describing IQCODE, we included three papers, representing data from 626 individuals. Of this total, 22% (N = 135/
626) were excluded because of prevalent dementia. There was substantial attrition; 47% (N = 295) of the study population received
reference standard assessment at first follow-up (three to six months) and 28% (N = 174) received reference standard assessment at final
follow-up (one to three years). Prevalence of dementia ranged from 12% to 26% at first follow-up and 16% to 35% at final follow-up.
The three studies were considered to be too heterogenous to combine, so we did not perform meta-analyses to describe summary
estimates of interest. Included patients were poststroke (two papers) and hip fracture (one paper). The IQCODE was used at three
thresholds of positivity (higher than 3.0, higher than 3.12 and higher than 3.3) to predict those at risk of a future diagnosis of dementia.
Using a cut-off of 3.0, IQCODE had a sensitivity of 0.75 (95%CI 0.51 to 0.91) and a specificity of 0.46 (95%CI 0.34 to 0.59) at
one year following stroke. Using a cut-off of 3.12, the IQCODE had a sensitivity of 0.80 (95%CI 0.44 to 0.97) and specificity of 0.53
(95C%CI 0.41 to 0.65) for the clinical diagnosis of dementia at six months after hip fracture. Using a cut-off of 3.3, the IQCODE
had a sensitivity of 0.84 (95%CI 0.68 to 0.94) and a specificity of 0.87 (95%CI 0.76 to 0.94) for the clinical diagnosis of dementia at
one year after stroke.
In generaI, the IQCODE was sensitive for identification of those who would develop dementia, but lacked specificity. Methods for
both excluding prevalent dementia at baseline and assessing for the development of dementia were varied, and had the potential to
introduce bias.
Authors’ conclusions
Included studies were heterogenous, recruited from specialist settings, and had potential biases. The studies identified did not allow us
to make specific recommendations on the use of the IQCODE for the future diagnosis of dementia in clinical practice. The included
studies highlighted the challenges of delayed verification dementia research, with issues around prevalent dementia assessment, loss to
follow-up over time, and test non-completion potentially limiting the studies. Future research should recognise these issues and have
explicit protocols for dealing with them.
P L A I N L A N G U A G E S U M M A R Y
Using a structured questionnaire (the IQCODE) to detect individuals who may go on to develop dementia
Background
Accurately identifying people with dementia is an area of public and professional concern. Dementia is often not diagnosed until late
in the disease, and this may limit timely access to appropriate health and social support. There is a growing interest in tests that detect
dementia at an early stage, before symptoms have become problematic or noticeable. One way to do this is to test a person and then
re-assess them over time to see if they have developed dementia.
Our review focused on the accuracy of a questionnaire-based assessment for dementia, called the IQCODE (Informant Questionnaire
for Cognitive Decline in the Elderly). We described whether the initial IQCODE score can identify people who will develop dementia
months or years after their first IQCODE assessment.
We searched electronic databases of published research studies, looking for all studies that looked at IQCODE and a later diagnosis of
dementia. We searched from the first available papers in scientific databases up to and including January 2016.
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Study characteristics
We found three relevant studies, all of which were carried out in specific hospital settings. Two papers only included patients with
acute stroke, and the other included those who had sustained a hip fracture. The papers differed in many other ways, so we we were
unable to estimate a summary of their combined results. In general, a ’positive’ IQCODE picked up patients who would go on to
develop dementia (good sensitivity), but mislabelled a number who did not develop dementia (poor specificity). We cannot make
recommendations for current practice, based on the studies we reviewed.
Quality of the evidence
The included studies demonstrated some of the challenges of research that follows people at risk of dementia over time. Not all the
studies had a robust method of ensuring that none of the included participants had dementia at the start of the study, and that only
new cases were identified. Similarly, many of the participants included at the start of the study were not available for re-assessment, due
to death or other illness.
The review was performed by a team based in research centres in the UK (Glasgow, Edinburgh, Oxford). We had no external funding
specific to this study, and we have no conflicts of interest that may have influenced our assessment of the research data.
B A C K G R O U N D
Dementia is a substantial and growing public health concern
(Herbert 2013; Prince 2013). Depending on the case defini-
tion used, contemporary estimates of dementia prevalence in the
United States are in the range of 2.5 to 4.5 million individuals.
Changes in population demographics will be accompanied by in-
creases in global dementia incidence and prevalence. Although the
magnitude of the increase in prevalent dementia is debated, there
is no doubt that absolute numbers of older adults with demen-
tia will increase substantially in the short to medium-term future
(Ferri 2005).
A diagnosis of dementia requires both cognitive and functional
decline. A syndrome of cognitive problems beyond those expected
for age and education, but not sufficient to impact on daily activ-
ities is also recognised. This possible intermediate state between
normal cognitive ageing and pathological change is often labelled
as mild cognitive impairment (MCI) or cognitive impairment, no
dementia (CIND), although a variety of other terms are also used.
For consistency, we use the term MCI throughout this review. A
proportion of individuals with MCI will develop a clinical de-
mentia state over time (estimated at 10% to 15% of MCI indi-
viduals annually), while others will improve or remain stable. All
definitions of this ’pre-dementia’ state are based on key criteria of
changes in cognition (subjective or reported by an informant) with
objective cognitive impairment, but preserved functional ability.
A key element of effectivemanagement in dementia is early, robust
diagnosis. Recent guidelines place emphasis on very early diag-
nosis to facilitate improved management, and to allow informed
discussions and planning with patients and carers (Cordell 2013).
An early or unprompted assessment paradigm needs to distinguish
early pathological change from normal states. Diagnosis of early
dementia orMCI is especially challenging. It is important to recog-
nise those who will progress to dementia, as identification of this
group may allow for targeted intervention. However, at present,
there is no accepted method for determining prognosis.
The ideal would be expert, multidisciplinary assessment, informed
by various supplementary investigations (neuropsychology, neu-
roimaging or other biomarkers). This approach is only really fea-
sible in a specialist memory service and is not suited to population
screening or case-finding.
In practice, a two-stage process is often used, with initial triage as-
sessments that are suitable for use by non-specialists used to select
those patients who require further detailed assessment (Boustani
2003). Various tools for initial cognitive screening have been de-
scribed (Brodaty 2002; Folstein 1975; Galvin 2005). Regardless
of the methods used, there is room for improvement, as obser-
vational work suggests that many patients with dementia are not
diagnosed (Chodosh 2004; Valcour 2000).
The initial assessment often takes the formof brief, direct cognitive
testing. Such an approach will only provide a snapshot of cogni-
tive function. However, a defining feature of dementia is cognitive
or neuropsychological change over time. Patients themselves may
struggle to make an objective assessment of personal change, and
so an attractive approach is to question collateral sources with suffi-
cient knowledge of the patient. These informant-based interviews
aim to retrospectively assess change in function. An instrument
that is prevalent in research and clinical practice, particularly in
Europe, is the Informant Questionnaire for Cognitive Decline in
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the Elderly (IQCODE) with questionnaire-based interviews. This
screening or triage tool is the focus of this review (Jorm 2004).
Traditional assessment tools for cognitive problems have defined
threshold scores that differentiate individuals likely to have de-
mentia from those with no dementia. As dementia is a progressive,
neurodegenerative disease, a population with cognitive problems
will have a range of test scores. Individuals with a pre-dementia
state, MCI, or indeed early dementia, may have screening test
scores that although not at a threshold suggestive of dementia, are
still abnormal for age. It seems plausible that a subthreshold score
on a screening test such as IQCODE could be predictive of future
dementia states, and so could be used to target those individuals
who may need follow-up or further investigation. This paradigm
of using an outcome of delayed verification of a dementia state
is commonly used in studies of the diagnostic properties of de-
mentia biomarkers, but theoretically, can be applied to direct or
informant-based assessment scales.
This review focused on the use of the IQCODE in individuals
without a firm clinical diagnosis of dementia, and assessed the
accuracy of IQCODE scores for delayed verification of a diagnosis
of dementia after a period of prospective follow-up.
Target condition being diagnosed
The target condition for this diagnostic test accuracy review was
the development of all cause dementia (incident clinical diagnosis).
Dementia is a syndrome characterised by cognitive or neuropsy-
chological decline, sufficient to interfere with usual functioning.
The neurodegeneration and clinical manifestations of dementia
are progressive.
Dementia remains a clinical diagnosis, based on history from the
patient and suitable collateral sources, and direct examination,
including cognitive assessment. There is no universally accepted,
ante-mortem, gold standard diagnostic strategy. We have chosen
expert clinical diagnosis as our gold standard (reference standard),
as we believe this ismost in keepingwith current diagnostic criteria
and best practice.
A diagnosis of dementia can be made according to various inter-
nationally accepted diagnostic criteria, with exemplars being the
World Health Organization International Classification of Dis-
eases (ICD) and the American Psychiatric Association Diagnostic
and Statistical Manual of Mental Disorders (DSM) for all cause
dementia and subtypes. The label of dementia encompasses vary-
ing pathologies, of which Alzheimer’s disease is themost common.
Diagnostic criteria are available for specific dementia subtypes,
that is, theNational Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’sDisease andRelatedDis-
orders Association (NINCDS-ADRDA) criteria for Alzheimer’s
dementia (McKhann 1984; McKhann 2011); the McKeith crite-
ria for Lewy Body dementia (McKeith 2005); the Lund criteria
for frontotemporal dementias (McKhann 2001); and theNINDS-
AIREN criteria for vascular dementia (Roman 1993).
We examined delayed verification of dementia, and so we have
described the properties of a standard, initial assessment (the IQ-
CODE) for detection of problems earlier in the disease journey
than frank dementia. Thus, our outcome of interest for this review
is a confirmed diagnosis at a point in time later than the initial
IQCODE testing. We did not pre-specify a minimum or maxi-
mum length of follow-up.
A proportion of participants included in relevant studies were
likely to have MCI, that is, cognitive problems beyond those ex-
pected for age and education but not sufficient to impact on daily
activities. The usual research definition of MCI is that described
by Petersen (Peterson 2004); and various subtypes have been pro-
posed within the rubric ofMCI.We collated information onMCI
described using any validated criteria, however, the focus of the
review was not IQCODE for the contemporaneous diagnosis of
MCI, but rather IQCODE for a future diagnosis of dementia.
These two constructs are related but not synonymous, as only a
proportion of individuals with MCI will develop dementia.
Index test(s)
Our index test was the Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE (Jorm 1988)).
The IQCODE was originally described as a 26-item informant
questionnaire that sought to retrospectively ascertain change in
cognitive and functional performance over a 10-year time period.
IQCODE was designed as a brief screen for potential dementia,
usually administered as a questionnaire given to the relevant proxy.
For each item, the chosen proxy scores change on a five-point ordi-
nal hierarchical scale, with responses ranging from 1: ’has become
much better’ to 5: ’has become much worse’. This gives a sum
score of 26 to 130 that can be averaged by the total number of
completed items, to give a final score of 1.0 to 5.0, where higher
scores indicate greater decline.
First described in 1989, use of the IQCODE is prevalent in both
clinical practice and research. A literature describing the properties
of IQCODE is available, including studies of non-English IQ-
CODE translations, studies in specific patient populations, and
modifications to the original 26-item direct informant interview
(Isella 2002; Jorm 1989; Jorm 2004). Versions of the IQCODE
have been produced in other languages including: Chinese,Dutch,
Finnish, French, Canadian French, German, Italian, Japanese, Ko-
rean, Norwegian, Polish, Spanish, and Thai (www.anu.edu.au/
iqcode/). A shortened 16-item version is also available; this mod-
ified IQCODE is common in clinical practice and has been rec-
ommended as the preferred IQCODE format (Jorm 2004). Fur-
ther modifications to the IQCODE are described, including fewer
items and assessment over shorter time periods. Our analysis in-
cluded all versions of IQCODE, but results for original and mod-
ified scales were not pooled. In this review, the term IQCODE
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refers to the original 26-item English language questionnaire as
described by Jorm. Other versions of IQCODE are described ac-
cording to the number of items and administration language (that
is, a 16-item IQCODE for Spanish speakers is described as IQ-
CODE-16 Spanish).
In the original IQCODE development and validation work, nor-
mative data were described, with a total score higher than 93 or an
average score higher than 3.31 indicative of cognitive impairment
(Jorm 2004). There is no consensus on the optimal threshold and
certainly no guidance on the use of subthreshold IQCODE scores
for delayed verification. In setting thresholds for any diagnostic
test, there is a trade-off between sensitivity and specificity, with
the preferred values partly determined by the purpose of the test.
This review completes a suite of Cochrane reviews describing
the test accuracy of IQCODE in various health care contexts
(Harrison 2014; Harrison 2015; Quinn 2014).
Clinical pathway
Dementia develops over a trajectory of several years and screening
testsmay be performed at different stages in the dementia pathway.
In this review, we considered any use of IQCODE as an initial
assessment for cognitive decline, and we did not limit studies to
a particular healthcare setting. We operationalised the various set-
tings where the IQCODEmay be used as secondary care, primary
care, and community.
In secondary care settings, individuals would have been referred
for expert input, but not exclusively due to memory complaints.
Opportunistic screening of adults presenting as unscheduled ad-
missions to hospitals would be an exemplar secondary care path-
way. The rubric of secondary care also included individuals re-
ferred to dementia and memory specific services. This population
would have had a high prevalence of cognitive disorders and mim-
ics. More individuals would have had a greater degree of prior cog-
nitive assessment than in other settings, but cognitive testing was
not always performed prior to memory service referral (Menon
2011).
In the general practice and primary care setting, the individual self-
presented to a non-specialist service because of subjective memory
complaints. Previous cognitive testing was unlikely, but prevalence
would be reasonably high.Using IQCODE in this setting could be
described as triage or case-finding. In the community setting, the
cohort was largely unselected and the approach may be described
as population screening.
The IQCODE delayed verification approach recognises that in
any of these settings or pathways, there will be a populationwho do
not yet have a cognitive syndrome that would warrant a dementia
label, but who nonetheless may progress to a frank dementia state.
If IQCODE has delayed verification utility, this population may
score less than expected on initial IQCODE assessment.
The IQCODE is not a diagnostic tool and was not designed to
be used as such. Rather, IQCODE would often be used as part
of an initial assessment, and based on test scores, more detailed
assessment may be required. However, in order to quantify the
test accuracy of the IQCODE, it was necessary to evaluate it as a
diagnostic test, against a gold standard of clinical diagnosis.
IQCODE is often used, and may have particular utility, as an ini-
tial assessment in a group of individuals considered to be at risk
of having or developing dementia. Here, the role of IQCODE
is identifying those who may need further detailed assessment or
follow-up. Although this description does not fulfil all the estab-
lished criteria to be considered a screening test (Wilson 1968), we
used the term ’screening’ in this review as a descriptor of this early
triage assessment.
Alternative test(s)
Several other dementia screening and assessment tools have been
described, for example, Folstein’s mini-mental state examination
(MMSE; Folstein 1975). These performance-based measures for
cognitive screening all rely on comparing single or multi-domain
cognitive testing against population-specific normative data.
Other informant interviews are also available. For example, the
AD-8 is an eight-question tool that requires dichotomous re-
sponses (yes or no) and tests for perceived changes in memory,
problem solving, orientation, and daily activities (Galvin 2005).
For this review, we focused on papers that described IQCODE di-
agnostic properties; we did not consider other cognitive screening
or assessment tools. Our IQCODE diagnostic test accuracy stud-
ies form part of a larger body of work by the Cochrane Dementia
and Cognitive Improvement Group that describes test properties
of all commonly used assessment tools (Appendix 1).
Rationale
There is no consensus on the optimal initial assessment for de-
mentia, and choice is currently dictated by experience with a par-
ticular instrument, time constraints, and training. A better under-
standing of the diagnostic properties of various strategies would
allow for an informed approach to testing. Critical evaluation of
the evidence base for screening tests or other diagnostic markers is
of major importance. Without a robust synthesis of the available
information, there is the risk that future research, clinical practice,
and policy will be built on erroneous assumptions about diagnos-
tic validity.
This review forms part of a body of work that describes the diag-
nostic properties of commonly used dementia tools. At present, we
are conducting single test reviews andmeta-analyses. However, the
intention is then to collate these data by performing an overview,
that will allow comparison of various test strategies.
O B J E C T I V E S
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Todetermine the diagnostic accuracy of the informant-based ques-
tionnaire IQCODE in a population free from dementia, for the
delayed diagnosis of dementia.
Secondary objectives
Where data were available, we planned to describe the following:
1. The delayed verification diagnostic accuracy of IQCODE at
various thresholds.We recognise that various thresholds or cut-off ’
scores have been used to define IQCODE screen-positive states,
and thus various subthreshold cut-points could be used to describe
individuals with cognitive problems not diagnostic of dementia.
We did not pre-specify IQCODE cut-points of interest, rather we
collected delayed verification test accuracy data for all cut-points
described in the primary papers.
2. Effects of heterogeneity on the reported diagnostic accuracy of
IQCODE for delayed verification dementia (see below).
Items of specific interest included case-mix of population, IQ-
CODE test format, time since index test, and healthcare setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
In this review we looked at the properties of IQCODE for diagno-
sis of the dementia state on prospective follow-up, that is, investi-
gating whether a certain score on IQCODE, that may or may not
be below the normal threshold, in a population free of dementia
at baseline assessment, is associated with the development of de-
mentia over a period of follow-up. The implication was that at the
time of testing, the individual had a cognitive problem sufficient
to be picked up on screening, but not yet meeting diagnostic cri-
teria for dementia. We described this paradigm as ’delayed verifi-
cation’ diagnostic test accuracy. Other Cochrane reviews covered
IQCODE for contemporaneous diagnosis of dementia (Harrison
2014; Harrison 2015; Quinn 2014).
We anticipated that the majority of studies would be performed
in secondary care settings. We included test studies performed in
other healthcare settings, and classified these as primary care or
community.
We did not include case-control studies, since they are known to
potentially overestimate properties of a test.
Wedidnot include case studies or sampleswith very small numbers
(for the purposes of this review, fewer than 10 participants), but
described them in the table of excluded studies.
There may be cases where settings were mixed, for example, a
population study ’enriched’ with additional cases from primary
care. If available, we considered separate data for patients fromeach
setting. If these data were not available, we treated these studies as
case-control studies, and did not include them in this review.
Participants
All adults (aged over 18 years) and with no formal diagnosis of
dementia were eligible.
We did not predefine exclusion criteria relating to the case-mix
of the population studied, but assessed this aspect of the study as
part of our assessment of heterogeneity. Where there was concern
that the participants were not representative, we explored this at
study level, using the ’Risk of bias’ assessment framework, outlined
below.
Index tests
Studies had to include (not necessarily exclusively) IQCODE as
an informant questionnaire for delayed verification.
IQCODE has been translated into a number of languages to fa-
cilitate international administration (Isella 2002). The properties
of a translated IQCODE in a cohort of non-English speakers may
differ from properties of the original English language question-
naire. We collected data on the principal language used for IQ-
CODE assessment.
For this review, we did not consider other cognitive screening or
assessment tools. Where a paper described the IQCODE with an
in-study comparison against another screening tool, we included
the IQCODE data only. Where IQCODE was used in combina-
tion with another cognitive screening tool, we included the IQ-
CODE data only.
Target conditions
We included any clinical diagnosis of all cause (unspecified) de-
mentia. Defining a particular dementia subtype was not required,
although, where available, these data were recorded.
Reference standards
Our reference standard was a clinical diagnosis of incident de-
mentia. We recognise that clinical diagnosis itself has a degree of
variability, but this is not unique to dementia studies and does
not invalidate the basic diagnostic test accuracy approach. We also
recognise the lack of an agreed ’gold standard’ reference for de-
mentia, but believe a clinical reference is most relevant to the re-
view topic, and in keeping with current best practice in dementia
accuracy research.
For our primary analysis, clinical diagnosis, we included all cause
(unspecified) dementia, using any recognised diagnostic criteria
(for example ICD-10, DSM-IV). A diagnosis of dementia may
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specify a pathological subtype; we included all common demen-
tia subtypes (for example,NINCDS-ADRDA, Lund-Manchester,
McKeith, NINCDS-AIREN). We did not define preferred diag-
nostic criteria for rarer forms of dementia (for example, alcohol-re-
lated,HIV-related, prion disease-related), andwe considered them
under our rubric of ’all cause’ dementia, rather than separately.
Clinicians may use imaging, pathology, or other data to aid diag-
nosis, however, we did not include diagnoses based only on these
data, without a corresponding clinical assessment. We recognise
that different iterations of diagnostic criteria may not be directly
comparable, and that diagnoses may vary with the degree or man-
ner in which the criteria have been operationalised (for example,
individual clinician versus algorithm versus consensus determina-
tion); we collected data on the method and application of the di-
agnosis of dementia for each study, and explored potential effects
as part of our assessment of risk of bias and generalisability. Use
of other (brief ) direct performance tests in isolation were not an
acceptable method for diagnosis.
We recognise that the diagnosis of dementia often comprises a
degree of informant assessment. Thus there was potential for in-
corporation bias. We explored the potential effects of this bias
through our ’Risk of bias’ assessment.
Search methods for identification of studies
We used a variety of information sources to ensure that we in-
cluded all relevant studies.Wedevised terms for electronic database
searching in conjunction with the Information Specialist at the
Cochrane Dementia and Cognitive Improvement Group. As part
of a body of work looking at cognitive assessment tools, we created
a sensitive search strategy designed to capture papers about de-
mentia test accuracy. We then assessed the output of the searches
to select those papers that could be pertinent to IQCODE, with
further selection for directly relevant papers, and those papers with
a delayed-verification methodology.
Electronic searches
We searched ALOIS, the specialised register of the Cochrane
Dementia and Cognitive Improvement Group (which includes
both intervention and diagnostic accuracy studies), MEDLINE
OvidSP, EmbaseOvidSP, PsycINFOOvidSP, BIOSIS Previews on
Thomson Reuters Web of Science, Web of Science Core Collec-
tion (includes Conference Proceedings Citation Index) on Thom-
son Reuters Web of Science, CINAHL EBSCOhost, and LILACS
BIREME. See Appendix 2 and Appendix 3 for the strategies run.
The original search date was 28 January 2013, with an updated
search performed on 16 January 2016.
We also searched sources specific to diagnostic accuracy andhealth-
care research assessment on 16 January 2016:
• MEDION database (Meta-analyses van Diagnostisch
Onderzoek: www.mediondatabase.nl);
• DARE (Database of Abstracts of Reviews of Effects in the
Cochrane Library);
• HTA Database (Health Technology Assessment Database in
the Cochrane Library);
• ARIF database (Aggressive Research Intelligence Facility:
www.arif.bham.ac.uk).
We applied no language or date restrictions to the electronic
searches and used translation services as necessary.
A single researcher (ANS), with extensive experience of systematic
reviews from theCochraneDementia andCognitive Improvement
Group, performed the initial screening of the search results. All
subsequent searches of titles, abstracts, and papers were performed
independently by paired assessors (TJQ, JKH & RSP).
Searching other resources
Grey literature: We identified grey literature by searching confer-
ence proceedings, theses, or PhD abstracts in Embasee, the Web
of Science Core Collection, and other databases already specified.
Handsearching:We did not perform handsearching. The evidence
for the benefits of handsearching are not well defined, and we
noted that a study specific to diagnostic accuracy studies suggested
little additional benefit of handsearching above a robust initial
search strategy (Glanville 2012) .
Reference lists: We checked the reference lists of all included stud-
ies and reviews in the field for further possible titles, and repeated
the process until we found no new titles (Greenhalgh 1997).
Correspondence: We contacted research groups who have pub-
lished or are conducting work on IQCODE for the diagnosis of
dementia, informed by results of the initial search.
We searched for studies in PubMed, using the ’related article’ fea-
ture. We examined key studies in citation databases of Science Ci-
tation Index and Scopus to identify any further studies that could
potentially be included.
Data collection and analysis
Selection of studies
The original search was done for the programme of reviews in
2013.One review author (ANS) screened all titles generated by the
initial electronic database searches for relevance. The initial search
was a sensitive, generic search, designed to include all potential de-
mentia screening tools. Two review authors (ANS, TJQ) selected
titles potentially relevant to IQCODE. Two authors in the IQ-
CODE review group (TJQ, PF) independently conducted further
review and selection from the long list. We reviewed potential IQ-
CODE-related titles, assessing all eligible studies as abstracts, and
assessed potentially relevant studies as full manuscripts against our
inclusion criteria. We resolved disagreement by discussion, with
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the potential to involve a third review author (DJS) as arbiter, if
necessary. We adopted a hierarchical approach to exclusion, first
excluding on the basis of index test and reference standard, and
then on the basis of sample size and study data. A focused update
search was performed in 2016, which sought to identify only IQ-
CODE studies with a delayed verification design. Two review au-
thors (TJQ, JKH) independently reviewed potential IQCODE-
related titles from this update, assessed the abstracts of all poten-
tially relevant studies, and the full manuscripts of eligible studies
against the inclusion criteria. We resolved disagreement by discus-
sion, with the potential to involve a third review author (DJS) as
arbiter if necessary.
Both in the original search and the update, where a studymay have
included useable data but these were not presented in the pub-
lished manuscript, or the data presented could not be extracted
to a standard two-by-two table, we contacted the authors directly
to request further information or source data. If authors did not
respond, or if the data were not available, we did not include
the study (labelled as ’data not suitable for analysis’ on the study
flowchart). If the same data set was presented in more than one
paper, we included the primary paper. We detailed the study se-
lection process in a PRISMA flow diagram.
Data extraction and management
We extracted data to a study-specific pro forma that included clin-
ical and demographic details of the participants, details of the set-
ting, details of IQCODE administration, and details of the de-
mentia diagnosis process.
Test accuracy data were extracted to a standard two-by-two table.
Two review authors (TJQ, JKH) independently extracted data.
The review authors were based in different centres and were
blinded to each other’s data until extraction was complete. We
then compared and discussed data pro formas with reference to the
original papers, resolving disagreements in data extraction by dis-
cussion, with the potential to involve a third review author (DJS)
as arbiter if necessary.
For each included paper, we detailed the flowof participants (num-
bers recruited, included, assessed) in a flow diagram.
Assessment of methodological quality
As well as describing test accuracy, an important goal of the diag-
nostic test accuracy (DTA) process is to improve study design and
reporting in dementia diagnostic studies. For this reason, we as-
sessed both methodological and reporting quality, using two com-
plementary processes.
We assessed the quality of study reporting using the dementia-
specific extension to the Standards for the Reporting of Diagnos-
tic Accuracy studies (STARD-dem) checklist (Noel-Storr 2014;
Appendix 4).
We assessed the methodological quality of each study, using
the Quality Assessment tool for Diagnostic Accuracy Studies
(QUADAS-2) tool (www.bris.ac.uk/quadas/quadas-2). This tool
incorporates domains specific to patient selection, index test, ref-
erence standard, and participant flow. Each domain is assessed for
risk of bias, and the first three domains are also assessed for appli-
cability. Operational definitions describing the use of QUADAS-
2 are detailed in Appendix 5. To create QUADAS-2 anchoring
statements specific to studies of dementia test accuracy, we con-
vened a multidisciplinary review of various test accuracy studies
with a dementia reference standard (Davis 2013; Appendix 6).
Paired, independent raters (TJQ and JKH), blinded to each other’s
scores, performed both assessments.We resolved disagreements by
further review and discussion, with the potential to involve a third
review author (DJS) as arbiter if necessary.
We did not useQUADAS-2 data to form a summary quality score,
but rather, we chose to present a narrative summary that described
studies that found high, low, or unclear risk of bias or concerns
regarding applicability, with corresponding tabular and graphical
displays.
Statistical analysis and data synthesis
Wewere principally interested in the test accuracy of IQCODE for
the delayed diagnosis of dementia using a dichotomous variable,
’dementia’ or ’no dementia’. Thus, we applied the current DTA
framework for analysis of a single test and fitted the extracted data
to a standard two-by-two data table showing binary test results
cross-classified with a binary reference standard. We repeated this
process for each IQCODE threshold score described. We further
repeated the process for each assessment where the reference stan-
dard was assessed at more than one follow-up.
Where data allowed, we usedReviewManager 5.3 (RevMan 2014)
to calculate sensitivity, specificity, and their 95% confidence in-
tervals (CIs) from the two-by-two tables abstracted from the in-
cluded studies, or using data supplied from authors. The delayed
verification nature of the included studies added a further level
of complexity as a proportion of individuals recruited at baseline
may be lost to subsequent review, and the delayed verification
assessment may be performed at varying times from the initial
IQCODE assessment. In the first instance, we applied the usual
DTA framework, describing common reference time points and
performing no imputation or adjustment for any drop-outs that
might have occurred. We acknowledge that such a reduction in
the data may represent a significant oversimplification.
We presented data graphically, using forest plots to allow basic
visual inspection and comparison of individual studies. Standard
forest plots with graphical representation of summary estimates are
not suited to quantitative synthesis of DTA data. If data allowed,
we had planned to calculate summary estimates of test accuracy.
In our protocol, we pre-specified that we would consider meta-
analyses if more than three studies with suitable data were avail-
able. We planned to use the bivariate approach to give summary
estimates of test accuracy at common thresholds and common
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time points, and to use the HSROC model to explore differing
thresholds across studies.
Investigations of heterogeneity
Heterogeneity is to be expected in DTA reviews, and we did not
perform formal analysis to quantify heterogeneity.
We included IQCODE studies that spanned various settings and
offered a narrative review of all studies. We presented basic test
accuracy statistics across all studies, and we assessed test accuracy
at the various follow-up periods and thresholds described in the
included studies.
In our protocol, we detailed planned assessments of heterogeneity
relating to age, case mix, clinical criteria for diagnosing dementia,
technical features of the testing strategy, and other factors specific
to the delayed verification analysis. These analyses were not pos-
sible with the data in this review.
Sensitivity analyses
In our protocol, we specified certain sensitivity analyses to explore
the sensitivity of any summary accuracy estimates to aspects of
study quality, such as nature of blinding and loss to follow-up,
guided by the anchoring statements developed in our QUADAS-
2 exercise. These analyses were not possible with the data in this
review.
Due to the potential for bias, we pre-specified that case-control
data were not included.
Assessment of reporting bias
Reporting bias was not investigated because of current uncertainty
about how it operates in test accuracy studies and in the interpre-
tation of existing analytical tools, such as the funnel plot.
R E S U L T S
Results of the search
Our search identified 16,543 citations, from which we identified
85 full-text papers for potential eligibility. We excluded 82 pa-
pers (Figure 1). Reasons for exclusion were: no IQCODE data
or unsuitable IQCODE data, small numbers (< 10) of included
participants, no clinical diagnosis of dementia, repeat data sets,
data not suitable for analysis (described in more detail in Selection
of studies), no data regarding delayed verification, wrong study
design, and case-control design (see Characteristics of excluded
studies).
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Figure 1. Study flow diagram.
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Eight studies required translation. We contacted 19 au-
thors to provide useable data, 16 of whom responded (see
Acknowledgements).
This review includes three studies, N = 626 participants (Summary
of findings 1). None of the included studies were described as pri-
mary delayed verification studies, and the original papers did not
have an exclusive delayed verification accuracy focus. We obtained
additional data from all three author groups in correspondence to
facilitate inclusion in the review.
Methodological quality of included studies
We described the risk of bias using the QUADAS-2 methodology
(Appendix 5), and we assessed reporting quality with STARDdem
(Appendix 7); our anchoring statements for the IQCODE are
summarised in Appendix 6. We did not rate any study as having
low risk of bias for all the categories of QUADAS-2 (Figure 2;
Figure 3).
Figure 2. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
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Figure 3. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
Patient selection/sampling
All studies were at low risk of bias for patient selection, based on
our pre-defined anchoring statements. All three were of cohort
design and avoided inappropriate exclusions. One study sought
a consecutive sample of admissions (Henon 2001). However, all
studies excluded those who did not have an informant to complete
the IQCODE assessment, and all excluded those who had pre-
existing dementia, thus, none recruited a consecutive sample of
admissions.
In all three studies, we felt there was low concern about the appli-
cability of the findings to the populations under study. Two stud-
ies were conducted in the acute stroke unit setting (Caratozzolo
2014; Henon 2001), and the final one was conducted on admis-
sions for acute hip fracture (Krogseth 2011), both of which were
considered common in-patient secondary care populations. This
grading does not suggest that results from these studies in specialist
areas could be extrapolated to an unselected population of older
adults.
All studies used a method of excluding prevalent dementia, 22%
(N = 135/626) of the total were assessed to have pre-stroke or pre-
fracture dementia. The methods for reaching this diagnosis varied.
In Krogseth 2011, determination of pre-fracture dementia was
based on a review of the patient’s medical records, including prior
cognitive testing, brain imaging, or both. This was combined with
their IQCODE, MMSE, and Clock-Drawing Test scores (Agrell
1998), and presented to two specialists who determined if the in-
dividual met DSM-IV criteria for dementia. In Caratozzolo 2014,
pre-stroke dementia was defined by having an existing diagnosis of
dementia using DSM-IV criteria. In Henon 2001, pre-stroke de-
mentia was defined as having an IQCODE score of 104 or greater,
which equates to a score of 4.0.
IQCODE (index test) application
One study was considered to be at high risk of bias in index test ap-
plication, as the threshold used to define test positivity was not pre-
specified, and was based on the baseline characteristics of recruited
participants (Krogseth 2011). In the other two studies, IQCODE
positivity was pre-specified at higher than 3.3 (Caratozzolo 2014),
and 3.0 (Henon 2001), respectively. This assessment was difficult
to operationalise for our delayed verification focus, where there
was no guidance on an appropriate IQCODE threshold.
For all three studies, there was low concern about the applicability
of the conduct or interpretation of the index test.
Dementia diagnosis (reference standard) application
Two studies were at high risk of bias in the use of the reference
standard (Henon 2001; Krogseth 2011). Henon 2001 reached a
reference standard diagnosis in a diagnostic case conference forum.
However, not all included participants received the same reference
standard, and where participants were not assessed, the index test
was used to determine the reference standard. Krogseth 2011 used
the results of the index test to inform the creation of the reference
standard diagnosis.
Caratozzolo 2014 was at low risk of bias in this domain, as the
reference standard diagnosis was made by clinicians blinded to the
results of the index test. However, the method for reference stan-
dard assessment was not described in the study abstract, and thus
the applicability was graded as unclear. In subsequent correspon-
dence with the author team, the method used was based on the
Itel-MMSE (Metitieri 2001), with a score less than 24, the Barthel
Index (Mahoney 1965), and an Instrumental Activities of Daily
Living scale that indicated the loss of more than one activity of
daily living. This defined states of ’possible post-stroke dementia’
and ’no dementia’; these categories were then appraised by a neu-
rologist using DSM-IV criteria. We felt the applicability of this
two-stage process was uncertain, and the grading of unclear was
maintained.
Flow and timing
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There was substantial attrition. The three studies had a baseline
population of N = 626, 47% (N = 295) of whom received the
reference standard assessment at the first follow-up period, which
ranged from three to six months, and 28% (N = 174) of whom
received the reference standard assessment at the final follow-up
period, which ranged from one to three years.
All three studies were at high risk of bias for the domain of flow
and timing. The longitudinal nature of the studies resulted in sig-
nificant attrition, either due to death or loss to follow-up. Missing
data for participants were an issue in all three studies.
Reporting quality
Reporting quality tools exist for various study designs. STARD-
dem guidance is structured around key aspects of reporting that is
required in test accuracy studies; reporting quality was described
for each study using the STARDdem guidance (Appendix 4),
which is presented in Appendix 7. Important limitations in report-
ing were the number, training, and expertise of the persons execut-
ing and reading the index tests and reference standard; blinding
of the readers of the index test and reference standard, and how
indeterminate results, missing data, and outliers of the index tests
were handled.
Findings
The included study characteristics are described in the
Characteristics of included studies, Summary of findings 1, and
Summary of findings 2.
Caratozzolo 2014 recruited 121 acute stroke inpatients, free of
dementia at baseline, and assessed them for the presence of de-
mentia at three months and one year of follow-up. IQCODE data
were available at baseline for all included participants, 114 were
assessed at three months, and 105 at one year, with all losses due
to death in the intervening period. The prevalence of dementia
was 25% at three months, and 35% at one year.
Using a cut-off of higher than 3.3, the IQCODE had a sensitivity
of 0.86 (95%CI 0.67 to 0.96) and a specificity of 0.90 (95%CI
0.81 to 0.95) for the clinical diagnosis of dementia at threemonths,
and a sensitivity of 0.84 (95%CI 0.68 to 0.94) and a specificity of
0.87 (95%CI 0.76 to 0.94) for the clinical diagnosis of dementia
at one year.
Henon 2001 recruited acute stroke inpatients, free of dementia
at baseline, and assessed them for the presence of dementia at six
months, one year, two years, and three years of follow-up. From an
initial sample of 169 individuals, there was significant attrition at
each follow-up period, due to patient death and unwillingness for
further assessment. At six months, 99 participants were assessed,
85 were assessed at one year, 65 were assessed at two years, and
69 participants were assessed at three years. Around 25% of the
participants had died by the six-month follow-up; this rose to 38%
by the three-year follow-up. When individuals were not assessed
by the study neurologist, the authors used additional means of
evaluating dementia status, including telephone contact with the
general practitioner or family members. Prevalence of dementia
was 26% at six months, 24% at one year, 20% at two years, and
16% at three years.
Using a cut-off of higher than 3.0, the IQCODE had a sensitivity
of 0.77 (95%CI 0.56 to 0.91) and a specificity of 0.51 (95%CI
0.39 to 0.63) for the clinical diagnosis of dementia at six months,
and a sensitivity of 0.75 (95%CI 0.51 to 0.91) and a specificity of
0.46 (95%CI: 0.34 to 0.59) at one year. At two years, the sensitivity
was 0.85 (95%CI 0.55 to 0.98) and specificity was 0.46 (95%CI:
0.32 to 0.61), and at three years, the sensitivity was 0.82 (95%CI
0.48 to 0.98) and specificity was 0.38 (95%CI 0.26 to 0.52) for
the clinical diagnosis of dementia.
Krogseth 2011 recruited hip fracture inpatients and evaluated the
effects of delirium on the risk of incident dementia at six-month
follow-up. Data on the IQCODE assessment at baseline were
missing for 25% (27/106) of included participants, leaving 82
who were assessed at baseline and at six months. Prevalence of
dementia at follow-up was 12%.
Using a cut-off of higher than 3.12, the IQCODEhad a sensitivity
of 0.80 (95% CI 0.44 to 0.97) and specificity of 0.53 (95C%CI
0.41 to 0.65) for the clinical diagnosis of dementia at six months.
We did not performmeta-analyses to describe summery estimates
of interest. In our protocol, we had pre-specified that more than
three studies would be required for a meta-analysis to be valid. We
were also mindful of the heterogeneity between the included stud-
ies, which described very different healthcare settings and patient
populations. Had we found a larger number of studies, we could
have pooled data and then investigated the effects of certain study
characteristics on the accuracy of estimates, using meta-regression,
however, with themodest number of studies in this review, such an
analysis was not possible. In view of the heterogeneity between the
three included studies, the lack of agreed threshold for IQCODE
positivity, and lack of common follow-up, we were also unable to
perform any of our pre-specified subgroup or sensitivity analyses.
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Summary of findings
Study ID Country Subjects at
Baseline (n)
M ean Age (yrs) IQCODE Version Language Dementia Diagno-
sis
Dementia preva-
lence at 1st
follow-up n/ as-
sessed
(%)
Timing
Dementia Preva-
lence at last fol-
low-up
n/ assessed
(%)
Timing
Other
Assessments
Caratozzolo
2014
Italy 158 68.4 to 77.4 16-item Italian DSM-IV 28/ 114
(24.6)
3 months
37/ 105
(35.2)
12 months
BI; IADL; Itel-
MMSE
Henon 2001 France 202 ≥ 40 26-item French ICD-10 26/ 99
(26.2)
6 months
11/ 69
(15.9)
3 years
MDRS, MADRS,
MMSE
Krogseth 2011 Norway 266 82.7 16-Item Norwegian DSM-IV 10/ 82
(12.2)
6 months
* CAM, MMSE, CDT,
ADL
Abbreviat ions: ADL- Act ivit ies in Daily Living; BI- Barthel Index; CAM- Confusion Assessment Method; CDT- Clock Drawing Test;
DSM- American Psychiatric Associat ion Diagnost ic and Stat ist ical Manual of Mental Disorders; IADL- Instrumental Act ivit ies
of Daily Living; ICD- Internat ional Classif icat ion of Disease; Itel-MMSE- Italian version of MMSE; MADRS- Montgomery-
Asberg Depression Rating Scale; MDRS- Matt is Dementia Rating Scale; MMSE- Mini-Mental State Examinat ion.
* only single t ime point of assessment
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What is the accuracy of the Informant Questionnaire for Cognitve Decline in the Elderly (IQCODE) test for the early
diagnosis of dementia when differing thresholds are used to define IQCODE positive cases?
Population Adults, f ree of dementia at baseline assessment, who were assessed using the IQCODE, some of
who will develop dementia over a period of follow-up. The implicat ion is that at the t ime of test ing,
the individual had a cognit ive problem suf f icient to be picked up on screening, but not yet meeting
dementia diagnost ic criteria
Setting We considered any use of IQCODE as an init ial assessment for cognit ive decline, and we did not
lim it studies to a part icular healthcare sett ing. We operat ionalised the various sett ings where the
IQCODE may be used as secondary care, primary care, and community
Index test Informant Quest ionnaire for Cognit ive Decline in the Elderly (IQCODE), administered to a relevant
informant. We restricted analyses to the tradit ional 26-item IQCODE and the commonly-used short
form IQCODE with 16 items
Reference Standard Clinical diagnosis of dementia made using any recognised classif icat ion system
Studies We included cross-sect ional studies but not case-control studies
Test Summary accuracy
(95% CI)
No. of part icipants
(timeframe)
Dementia
prevalence
Implications, Quality
and Comments
IQCODE cut-off 3.0 At six months: Sensit iv-
ity 0.77 (0.56 to 0.91)
; Specif icity 0.51 (0.39
to 0.63)
At one year: Sensit iv-
ity 0.75 (0.51 to 0.91)
; Specif icity 0.46 (0.34
to 0.59)
At two years: Sensit iv-
ity 0.85 (0.55 to 0.98)
; Specif icity 0.46 (0.32
to 0.61)
At three years: Sensit iv-
ity 0.82 (0.48 to 0.98)
; Specif icity of 0.38 (0.
26 to 0.52)
From 1 study:
99 (at 6 months)
85 (at 1 year)
65 (at 2 years)
69 (at 3 years)
26% (at 6 months)
24% (at 1 year)
20% (at 2 years)
16% (at 3 years)
Using three thresholds
to def ine IQCODE test
posit ivity, the IQCODE
appeared to be rela-
t ively sensit ive in diag-
nosing dementia at fol-
low-up over 3 months
to 3 years
All included part ic-
ipants were hospi-
talised either for acute
stroke or hip f racture.
The f indings could not
be pooled and do not
allow for recommenda-
t ions for clinical prac-
t ice
IQCODE cut-off 3.12 At six months: Sensit iv-
ity 0.80 (0.44 to 0.97)
; Specif icity 0.53 (0.41
to 0.65)
From 1 study:
82 (at 6 months)
12% (at 6 months)
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IQCODE cut-off 3.3 At three months: Sen-
sit ivity 0.86 (0.67 to 0.
96); Specif icity 0.90 (0.
81 to 0.95)
At one year: Sensit iv-
ity 0.84 (0.68 to 0.94)
; Specif icity 0.87 (0.76
to 0.94)
From 1 study:
114 (at 3 months)
105 (at 1 year)
25% (at 3 months)
35% (at 1 year)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
Our review identified three heterogeneous studies, with follow-up
evaluation of dementia at time points between three months and
three years. The included studies all reported on patients at high
risk of developing a cognitive syndrome due to either delirium or
stroke.
The IQCODE was used at three thresholds of positivity (higher
than 3.0, higher than 3.12, and higher than 3.3) to predict those
at risk of a future diagnosis of dementia. Using the higher than
3.3 threshold, Caratozzolo 2014 found a modest sensitivity with
higher specificity for identifying those who would develop de-
mentia at three months and one year of follow-up. For the lower
thresholds of higher than 3.0 and higher than 3.12, used byHenon
2001 and Krogseth 2011 respectively, the IQCODE was again
modestly sensitive, but lacked specificity. Test accuracy fell over
time, with significant attrition of participants limiting the num-
bers available at follow-up, and the confidence intervals associated
with the summary properties widening as a consequence.
Methods for excluding prevalent dementia at baseline were varied,
and all had potential for bias. Defining pre-stroke dementia, based
on a high IQCODE score, was not ideal for a study of IQCODE
properties, albeit this was not the authors’ main focus in this study
(Henon 2001). Case-note review for a label of dementia was likely
to miss a proportion with early dementia (Caratozzolo 2014).
These approaches had the potential to bias the test accuracy results,
as they may have falsely reduced or inflated the disease prevalence.
The method of assessing for the reference standard was also varied,
with Henon 2001 using indirect assessments, including general
practitioner data and telephone follow-up. Although this method
sought to reduce losses to follow-up by using proxy information, it
had the potential to dilute the quality and certainty of the reference
standard assessment, which may have lead to misclassification.
Strengths and weaknesses of the review
Strengths and weaknesses of the included studies
Our risk of assessment of internal and external validity, using the
QUADAS-2 tool, identified issues across many aspects of study
design and conduct. This reflected both the methodological chal-
lenges of conducting cognitive studies with prospective follow-up
and the challenges for reviewers of applying a quality assessment
tool that is better suited to classical cross-sectional test accuracy
reports.
All three studies recruited from secondary care inpatient set-
tings, two with an acute stroke focus (Caratozzolo 2014; Henon
2001), and the other describing cognition following hip fracture
(Krogseth 2011). These were selected populations who had expe-
rienced physiological insult and brain injury (for themajority) and
who were at high risk of subsequently developing dementia (Bejot
2011; Davis 2012). This would increase the prevalence of our ref-
erence standard at follow-up and so limited the generalisability
of the findings to other non-acute settings. We did not identify
any studies that evaluated the performance of the IQCODE in
identifying those who would go on to develop dementia without
the presence of an acute event at the time of assessment.
To align with the delayed verification focus, clarifying dementia
status at baseline was fundamental to the study design. There is
no guidance on the preferred strategy for retrospectively assessing
dementia status following a major insult such as stroke or fracture
(McGovern 2016). The definition of pre-stroke dementia used
by Henon 2001, used the IQCODE in isolation and had more
potential for bias than the clinical assessment method used by
Krogseth 2011. Caratozzolo 2014 did not actively assess dementia
at the time of first presentation, instead relying on individuals
having an established diagnosis. This approach may have meant
that individuals with undiagnosed dementia were included in the
analysis, as it is known that dementia is under-diagnosed in those
who present for acute hospital care (Sampson 2009).
The use of IQCODE varied across the studies. We note, in com-
mon with other IQCODE reviews, that availability of an infor-
mant was not guaranteed. This immediately created potential for
bias as those with no available informant were likely to differ from
those who had someone that could complete the IQCODE. The
studies used IQCODE cut-offs that differed from those used to
indicate probable dementia; this was appropriate, as the purpose
of testing was not to diagnose contemporary dementia but to look
at a future risk.
The choice of IQCODE cut-off used was interesting, with Henon
2001 using any score above 3.0 (where 3.0 indicated no change
over the last ten years). This may explain the high sensitivity but
poor specificity of the tool. There is no guidance on a suitable cut-
off if using the IQCODE to assess future risk of dementia, but we
would assume that the threshold used would be lower than that
used to define dementia. The cut-off of 3.3 used in Caratozzolo
2014 has been used to define contemporaneous dementia in previ-
ous studies (Harrison 2014; Harrison 2015). Whether the initial
IQCODE was assessing for a pre-dementia state or was assessing
for early undiagnosed dementia is debatable. The follow-up peri-
ods (in months) used in some of the studies seemed rather short
to allow for the development of incident dementia. The ’natural
history’ of cognitive change following stroke and fracture are not
well described (Brainin 2015), and this further limited the inter-
pretation of our results. There is no consensus on the optimal time
point to assess for progression of dementia. Although our review
did not have an MCI focus, the MCI literature suggests that it
can take several years for a substantial proportion of patients to
’convert’ to dementia (Ritchie 2015). The population of inter-
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est in this review had a dementia syndrome, but at a very early
stage. Even if this population progressed at a faster rate than MCI
convertors, follow-up would still have to be in the order of years,
rather than months. We pre-specified that we would assess for use
of interventions that may impact on the usual cognitive trajectory.
No studies gave this level of detail, but arguably, this was not an
issue, since we currently have no evidence-based intervention that
impacts meaningfully on cognitive decline.
The assessment of the reference standard, clinical diagnosis of de-
mentia, also varied between studies. As with other reviews of IQ-
CODE, we noted the possible biases from the incorporation of
the index test (IQCODE) into the reference standard assessment.
This bias may have been difficult to avoid, as our chosen refer-
ence standard, clinical assessment of dementia, is itself partly based
on structured collateral history from an informant. The question
around timing of assessment for our reference standardwas equally
challenging.
Although the follow-up was not particularly long, there was sub-
stantial attrition over time. This reflected the sampling frame; both
stroke and fractured neck of femur are associated with short to
medium-term mortality and institutionalisation. The loss to fol-
low-up was unlikely to be random, and those at greatest risk of
dementia were likely to be over represented in the population with
no follow-up assessment. This explained the counterintuitive find-
ing of decreasing prevalence of dementia over time in the study
with the longest follow-up (Henon 2001). There is no consensus
on how to deal with missing data in the context of competing
risk for a delayed verification test accuracy design. However, this
situation is likely to be common to other studies that look at the
prospective development of dementia in an older adult cohort.
To allow a comprehensive assessment of the included studies,
we complemented our QUADAS-2 review with an assessment of
quality of reporting. We used a dementia-specific extension to
STARD (STARDdem (Noel-Storr 2014)), but as our chosen pa-
pers were not framed as test accuracy studies per se, it was diffi-
cult to apply the STARDdem criteria. Accepting this caveat, our
STARDdem assessment highlighted some limitations in reporting
that seemed to be common to other dementia test accuracy studies.
Lack of detail on how missing data, uninterpretable results, and
losses to follow-up were accounted for in the papers was a concern,
and we would urge greater detail and transparency around these
issues for future studies.
Strengths and weaknesses of the review process
The review benefits from a robust searchmethodology applied to a
targeted population. This identified only three studies suitable for
inclusion, none of whichwere primarily designed as diagnostic test
accuracy studies. We would argue that this finding reflects a lack of
research in this area, rather than an overly focused search strategy,
as an equivalent search identified substantial numbers of studies
assessing IQCODE’s use in secondary care (Harrison 2015), and
community settings (Quinn 2014).
We operated no exclusions with regard to study language or year of
publication. As part of the suite of reviews describing IQCODE,
we have contacted research teams with an interest in cognitive
screening to check for unpublished or in press original data.Where
reporting was not clear in the included manuscript, we contacted
the study authors, who supplied additional details; this enabled us
to include data from all three of the studies in this review.
The review is strengthened by the application of formal, dementia-
specific tools for the assessment of methodological and reporting
quality. We used QUADAS-2-based anchoring statements specifi-
cally developed for use with studies that have a cognitive index test
or reference standard (Davis 2013). Our complementary assess-
ment of reporting used the dementia-focused extension to stan-
dard guidelines STARDdem (Noel-Storr 2014). Although these
tools were the most appropriate for our study question, they were
primarily developed for cross-sectional test accuracy work, and we
experienced some difficulty in aligning themwith the delayed ver-
ification approach.
The delayed verification research design is frequently used in stud-
ies of dementia biomarkers, particularly those biomarkers that pur-
port to define a pre-clinical stage of disease. In designing our suite
of test accuracy reviews for IQCODE, we included the delayed
verification design.With hindsight, delayed verification is difficult
to operationalise with questionnaire-based cognitive testing. The
complexity increases when considering IQCODE, a tool that is
based on symptoms over the preceding ten years. Thus, we were
describing the use of a retrospective assessment for assigning po-
tential prospective disease status.
Comparisons with previous research
This review forms part of a series of reviews describing infor-
mant-based cognitive screening tools. Other reviews describing
IQCODE use in a primary care (Harrison 2014), community
(Quinn 2014) or hospital context (Harrison 2015), are available.
The heterogeneity of approaches used to define IQCODE posi-
tivity is in common with the previous reviews in the series.
We set a specific review question around IQCODE assessment
in a population with no dementia. Other papers have used base-
line IQCODE and prospective follow-up in different and perhaps
more clinically meaningful ways. Jackson 2014, one of the studies
excluded from this review, took an alternative approach to using
the IQCODE as a tool for detecting dementia. This test accuracy
study used the IQCODE at the time of acute hospital presenta-
tion for delirium and then re-evaluated individuals at three-month
follow-up. This evaluation allowed for the exclusion of ongoing
delirium and evaluation of the status of the individual following
their acute admission, seeking to identify undiagnosed dementia.
Using the IQCODE at a cut-off of higher than 3.65 offered the
most favourable results (Jackson 2014).
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Applicability of findings to the review question
The delayed verificationmodel in test accuracy has been developed
to evaluate any test that suggests it can identify those who have
preclinical dementia. This area of research is dominated by the
desire to identify and define biomarkers of early disease, matched
with an understandable desire to identify targets for therapeutic
intervention to prevent or delay disease progression. Intuitively, it
should hold that neuropsychological assessments, both direct and
informant-based, should identify such individuals, although data
in this area have been very limited. This review identified some of
the key challenges in conducting such studies, primarily attrition
over time, although in both cases, acutely unwell hospitalised older
adultswere the subjects, whomay bemore prone to earlymortality.
As a tool for delayed verification, the IQCODE has potential lim-
itations, and may not be suited to detecting pre-clinical disease. In
the included papers, it is debatable what the IQCODE is detect-
ing. Although the papers describe excluding prevalent dementia,
the assessment of dementia was not robust in all the studies and
it is likely that patients with early (undiagnosed) dementia were
included and ’conversion’ to dementia at follow-up simply repre-
sented progression of the underlying disease. The included papers
did not exclude participants with baseline MCI, who were also
likely to make up a proportion of the ’convertors’ to dementia.
We specified a number of subgroup and sensitivity analyses of
interest, but the limited data available precluded our progressing
these. Questions remain around the potential differential proper-
ties of delayed verification when considering an insidious, progres-
sive neurodegenerative process like Alzheimer’s Disease dementia
and major neurocognitive disorders that can have a more abrupt
onset, such as vascular cognitive impairment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The studies identified did not allow us to make specific recom-
mendations on the use of the IQCODE for the early diagnosis
of dementia in clinical practice. Indeed, it is debatable whether
IQCODE is suited to this purpose. However, our review question
was not irrelevant, as IQCODE is used in practice to predict future
cognition in certain areas, such as acute stroke (McGovern 2016).
If IQCODE is to be used in this way, the limited available data
suggest that it is sensitive but not sufficiently specific to inform
clinical decision-making. In this situation, clinicians may wish to
complement the IQCODE with another more specific baseline
assessment, or they may wish to adopt a two-stage screening, with
initial IQCODE testing and then further testing of all ’positive’
cases with a more specific tool.
Implications for research
The available evidence suggests that researching the IQCODE as
a diagnostic tool for the delayed verification of dementia is chal-
lenging, with significant loss to follow-up over time affecting esti-
mates of diagnostic accuracy. Future work must be explicit about
this issue and how to deal with losses. This may require an assess-
ment of the nature of reference standard assessment procedures,
and whether comprehensive face-to-face assessment can be per-
formed in all cases. The adequacy of alternative approaches, such
as telephone assessment, would need to be established, given that
the gold standard, clinical diagnosis of dementia, requires a multi-
dimensional approach. An alternative approach may be the use of
data linkage technology to ascertain diagnostic status over longitu-
dinal follow-up. However, such approaches may be limited by the
recording of dementia diagnosis on healthcare records and death
certificates, which is known to be sub-optimal (Romero 2014),
and the risk of missing those who have not yet received a formal
diagnosis (Bamford 2007).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Caratozzolo 2014
Study characteristics Study characteristics
Patient sampling Inpatients hospitalised for acute stroke in an Italian hospital over an 8-month period
Patient characteristics and set-
ting
All inpatients admitted to the neurological clinic of an Italian hospital for a suspected acute cere-
brovascular event were eligible for inclusion
Participants were those who had: experienced an acute stroke, a diagnosis made by neurologists
based on clinical symptoms and neuroimaging, and the availability of a reliable caregiver for each
patient. Individuals known to have a diagnosis of dementia were excluded as were those experiencing
a transient Ischaemic attack
Index tests IQCODE, 16-item, Italian language
Target condition and reference
standard(s)
Clinical diagnosis of dementia using DSM-IV criteria, diagnosed by a neurologist
Assessment of reference standard not described in the abstract or original paper. In correspondence
with authors, the assessment was conducted blinded to results of IQCODE
Flow and timing A total of 222 patients were evaluated, 64 of whom were excluded as they fulfilled the exclusion
criteria or did not agree to participate in the study
158 were entered into the study, 37 of whom were diagnosed with having pre-stroke dementia and
excluded, leaving 121 participants in the study
At three months, 114 were assessed (five died during hospitalisation and two died during the follow-
up period), and at one year, 105 were assessed (nine died between three- and twelve-month follow-
up)
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Caratozzolo 2014 (Continued)
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Low Unclear
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Were all patients included in the
analysis?
No
High
Henon 2001
Study characteristics Study characteristics
Patient sampling Consecutive sample admitted to the stroke unit, excluding those with pre-stroke dementia (defined
as IQCODE > 104), over a 28-week period
Patient characteristics and set-
ting
169 patients admitted to the acute stroke unit of a French university hospital. Participants were
those experiencing an acute stroke, aged > 40 years, Caucasian, fluent French speakers who resided
in the Lille community
Index tests IQCODE 26-item, French language
Target condition and reference
standard(s)
Clinical dementia diagnosis using ICD-10, applied at a diagnostic case conference that included
the assessing neurologist and two specialist neuropsychologists, using data from neuropsychological
testing or information from family or general practitioner, where formal testing was not possible,
including a further IQCODE assessment
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Henon 2001 (Continued)
Flow and timing 258 potentially eligible patients at baseline, 56 of whom were excluded due to lack of informant or
informant availability within 48 hours of stroke admission and 33 excluded due to the presence of
pre-stroke dementia
Follow-up was either a neurologist visit or telephone contact with the patient’s family or the patient’s
general practitioner. Follow-up intervals were at 6 months, 1 year, 2 years, and 3 years post-event
65 died before the initial follow-up visit at 6 months and there was ongoing loss of participants;
127 at 6 months, 117 at 1 year, 111 at 2 years, and 104 at 3 years
Not all recruited participants were prepared to be evaluated at follow-up; where this was the case,
or they had died in the interval, information was obtained from their general practitioner or family,
including an IQCODE assessment
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
High High
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
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Henon 2001 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Were all patients included in the
analysis?
No
High
Krogseth 2011
Study characteristics Study characteristics
Patient sampling Hip fracture patients admitted to two Norwegian hospitals over a one-year period
Patient characteristics and set-
ting
106 patients who were admitted acutely with a hip fracture and operated on in two Norwegian
hospitals. Eligibility was based on being over 65 years old, able to speak Norwegian, and length of
stay > 48 hours. Exclusions were made for those with severe aphasia, head trauma, terminal illness,
and prior inclusion in the study
Index tests IQCODE-16 item, Norwegian
Target condition and reference
standard(s)
An assessment of clinical diagnosis of dementia using DSM-IV criteria was made at two points
during the study, at baseline and at six-month follow-up. The diagnosis was made by two study
clinicians (one specialist in geriatric medicine and one specialist in geriatric psychiatry)
At baseline, data were extracted from the participants’ medical records for evidence of previous
cognitive testing, hypothyroidism andB12deficiency, and brain imaging. These datawere combined
with admission MMSE and CDT results and the pre-fracture IQCODE from their caregiver
At 6-month follow-up, diagnosis was made using the results of cognitive testing, informant infor-
mation about change in cognitive function post-fracture, and the report of the assessing physician.
The assessing physician had made home visits for all included participants, conducting structured
interviews and comprehensive cognitive testing
Flow and timing 266 eligible patients, 92 of whom were lost to follow-up at six months (47 died, 35 declined, 2
moved, and 8 were participating in competing study). A further 65 were excluded as they were
diagnosed with pre-fracture dementia, and 3 in whom pre-fracture cognition could not be assessed,
leaving 106 participants with assessment at six months
Not all of the included participants had available data for a baseline IQCODE (index test assessment)
, 27 were missing
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
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Krogseth 2011 (Continued)
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
High High
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Were all patients included in the
analysis?
No
High
IQCODE = Informant Questionnaire on Cognitive Decline in the Elderly
DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th revision
MMSE = Mini-mental State Examination
CDT = Clock Drawing Test
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abreu 2008 not delayed verification
Blackburn 2013 data not suitable for analysis
Bloomfield 2012 wrong study design
Bosboom 2013 wrong study design
Burke 2014 no original data
Burton 2015 review article
Butt 2008 data on fewer than 10 subjects
Bystad 2013 review article
Cherbuin 2008 no new data
Cherbuin 2012 no original data
Cruz-Orduna 2012 no delayed verification
de Jonge 1997 data not suitable for analysis
Dekkers 2009 data not suitable for analysis
Diefeldt 2007b no new data
Ehrensperger 2010 data not suitable for analysis
Eramudugolla 2013 wrong study design
Farias 2002 unsuitable reference standard
Finneli 2009 data not suitable for analysis
Fuh 1995 case-control study
Garcia 2002 not delayed verification
Girard 2014 unsuitable reference standard
Goncalves 2011 not delayed verification
Hancock 2009 not delayed verification
31Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of
healthcare settings (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Harwood 1997 not delayed verification
Hayden 2003 data on fewer than 10 subjects
Hollands 2015 unsuitable reference standard
Isella 2002 data not suitable for analysis
Isella 2006 case-control design
Jackson 2014 no delayed verification
Jorm 1988a not delayed verification
Jorm 1989 data not suitable for analysis
Jorm 1991 not delayed verification
Jorm 1994 not delayed verification
Jorm 1996A unsuitable reference standard
Jorm 1997 no new data
Jorm 2000 unsuitable reference standard
Jorm 2000a not delayed verification
Jorm 2003 no new data
Jorm 2004 no new data
Kathriarachi 2001 not delayed verification
Khachaturian 2000 data not suitable for analysis
Knaefelc 2003 not delayed verification
Larner 2010 two types of dementia rather than dementia versus no dementia
Larner 2013 review article
Law 1995 not delayed verification
Li 2012 unsuitable reference standard
Lin 2013 review article
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(Continued)
Louis 1999 case-control design
Mackinnon 1998 not delayed verification
Mackinnon 2003 not delayed verification
Mimori 2000 no new data
Morales 1995 not delayed verification
Morales 1997a not delayed verification
Morales 1997b not delayed verification
Morales-Gonzalez 1992 not delayed verification
Mulligan 1996 not delayed verification
Narasimhalu 2008 not delayed verification
Ozel-kizel 2010 not delayed verification
Peroco 2009 not delayed verification
Potter 2009 data not suitable for analysis
Razavi 2011 not delayed verification
Ritchie 1992 data not suitable for analysis
Rodriguez-Molinero 2010 unsuitable reference standard
Rovner 2012 data not suitable for analysis
Sanchez 2009 unsuitable reference standard
Schofield 2006 data not suitable for analysis
Senanorong 2001 not delayed verification
Sikkes 2010 not delayed verification
Siri 2006 not delayed verification
Srikanth 2006 not delayed verification
Starr 2000 unsuitable reference standard
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(Continued)
Tang 2003 not delayed verification
Thomas 1994 not delayed verification
Tokuhara 2006 not delayed verification
Wierderholt 1999 data not suitable for analysis
Wolf 2009 unsuitable reference standard
Yamada 2000 not delayed verification
Zevallos-Bustamente 2003 not delayed verification
Zhang 2003 data not suitable for analysis
Zhou 2002 not delayed verification
Zhou 2003 no new data
Zhou 2004 no new data
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 IQCODE any threshold
prediction of dementia at three
months
1 114
2 IQCODE any threshold
prediction of dementia at 6
months
2 181
3 IQCODE any threshold
prediction dementia at 12
months
2 190
4 IQCODE any threshold
prediction of dementia at two
years
1 65
5 IQCODE any threshold
prediction on dementia at three
years
1 69
Test 1. IQCODE any threshold prediction of dementia at three months.
Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings
Test: 1 IQCODE any threshold prediction of dementia at three months
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Caratozzolo 2014 24 9 4 77 0.86 [ 0.67, 0.96 ] 0.90 [ 0.81, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. IQCODE any threshold prediction of dementia at 6 months.
Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings
Test: 2 IQCODE any threshold prediction of dementia at 6 months
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Henon 2001 20 36 6 37 0.77 [ 0.56, 0.91 ] 0.51 [ 0.39, 0.63 ]
Krogseth 2011 8 34 2 38 0.80 [ 0.44, 0.97 ] 0.53 [ 0.41, 0.65 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. IQCODE any threshold prediction dementia at 12 months.
Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings
Test: 3 IQCODE any threshold prediction dementia at 12 months
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Caratozzolo 2014 31 9 6 59 0.84 [ 0.68, 0.94 ] 0.87 [ 0.76, 0.94 ]
Henon 2001 15 35 5 30 0.75 [ 0.51, 0.91 ] 0.46 [ 0.34, 0.59 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. IQCODE any threshold prediction of dementia at two years.
Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings
Test: 4 IQCODE any threshold prediction of dementia at two years
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Henon 2001 11 28 2 24 0.85 [ 0.55, 0.98 ] 0.46 [ 0.32, 0.61 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. IQCODE any threshold prediction on dementia at three years.
Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings
Test: 5 IQCODE any threshold prediction on dementia at three years
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Henon 2001 9 36 2 22 0.82 [ 0.48, 0.98 ] 0.38 [ 0.26, 0.52 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A P P E N D I C E S
Appendix 1. Commonly used cognitive assessment or screening tools
TEST Cochrane DTA review published/in progress
Mini-mental state examination (MMSE) YES
GPcog YES
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(Continued)
Minicog YES
Memory Impairment Screen (MIS) Still available
Abbreviated mental testing Still available
Clock-drawing tests (CDT) Still available
Montreal Cognitive Assessment (MoCA) YES
IQCODE (informant interview) YES
AD-8 (informant interview) YES
For each test, the planned review will encompass diagnostic test accuracy in community; primary and secondary care settings. As well
as standard diagnosis, where applicable reviews will also describe delayed verification design trials.
Appendix 2. Search strategies
Source Search strategy Hits retrieved
1. MEDLINE In-process and other non-
indexed citations and MEDLINE Ovid SP
(1950 to 16 January 2016)
1. IQCODE.ti,ab.
2. “informant questionnaire on cognitive
decline in the elderly”.ti,ab
3. “IQ code”.ti,ab.
4. (“informant* questionnair*” adj3 (de-
ment* or screening)).ti,ab
5. (“screening test*” adj2 (dement* or
alzheimer*)).ti,ab.
6. or/1-5
Apr 2011: 291
Jul 2012: 39
Jan 2013: 19
Jan 2016: 46
2. Embase Ovid SP
1980 to 16 January 2016
1. IQCODE.ti,ab.
2. “informant questionnaire on cognitive
decline in the elderly”.ti,ab
3. “IQ code”.ti,ab.
4. (“informant* questionnair*” adj3 (de-
ment* or screening)).ti,ab
5. (“screening test*” adj2 (dement* or
alzheimer*)).ti,ab.
6. or/1-5
Apr 2011: 356
Jul 2012: 49
Jan 2013: 44
Jan 2016:
166
3. PsycINFO Ovid SP
1806 to January week 2 2016
1. IQCODE.ti,ab.
2. “informant questionnaire on cognitive
decline in the elderly”.ti,ab
3. “IQ code”.ti,ab.
4. (“informant* questionnair*” adj3 (de-
Apr 2011: 215
Jul 2012: 28
Jan 2013: 17
Jan 2016:
50
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(Continued)
ment* or screening)).ti,ab
5. (“screening test*” adj2 (dement* or
alzheimer*)).ti,ab.
6. or/1-5
4. BIOSIS Previews (Thomson Reuters
Web of Science)
1926 to 15 January 2016
Topic=(IQCODE OR “informant ques-
tionnaire on cognitive decline in the el-
derly” OR “IQ code”) AND Topic=(de-
ment* OR alzheimer* OR FTLD OR
FTD OR “primary progressive aphasia”
OR “progressive non-fluent aphasia” OR
“frontotemporal lobar degeneration” OR
“frontolobar degeneration” OR “frontal lo-
bar degeneration” OR “pick* disease” OR
“lewy bod*”)
Timespan=All Years. Databases=
SCI-EXPANDED, SSCI, A&HCI, CPCI-
S, CPCI-SSH, BKCI-S, BKCI-SSH
Lemmatization=On
Apr 2011: 84
Jul 2012: 12
Jan 2013: 2
Jan 2016: 9
5. Web of Science Core Collection (in-
cludes Conference Proceedings Citation
Index; Thomson Reuters Web of Science)
1945 to 15 January 2016
Topic=(IQCODE OR “informant ques-
tionnaire on cognitive decline in the el-
derly” OR “IQ code”) AND Topic=(de-
ment* OR alzheimer* OR FTLD OR
FTD OR “primary progressive aphasia”
OR “progressive non-fluent aphasia” OR
“frontotemporal lobar degeneration” OR
“frontolobar degeneration” OR “frontal lo-
bar degeneration” OR “pick* disease” OR
“lewy bod*”)
Timespan=All Years. Databases=
SCI-EXPANDED, SSCI, A&HCI, CPCI-
S, CPCI-SSH, BKCI-S, BKCI-SSH
Lemmatization=On
Apr 2011: 184
Jul 2012: 24
Jan 2013: 13
Jan 2016: 56
6. LILACS BIREME (Latin American
andCaribbeanHealth Science Information
database)
(1982 to 15 January 2016)
“short-IQCODE” OR IQCODEOR “IQ
code” OR “Informant Questionnaire” OR
“Informant Questionnaires”
Apr 2011: 10
Jul 2012: 0
Jan 2013: 0
Jan 2016: 2
7. CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature)
(1982 to 15 January 2016)
S1 TX IQCODE
S2 TX “informant questionnaire”
S3 TX “IQ code”
S4 TX screening instrument
S5 S1 or S2 or S3 or S4
S6 (MM “Dementia+”)
S7 TX dement*
S8 TX alzheimer*
S9 S6 or S7 or S8
S10 S5 and S9
Apr 2011: 231
Jul 2012: 53
Jan 2013: 12
Jan 2016: 70
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(Continued)
8. Additional review sources:
• MEDION database (searched 15
January 2016 for all dates)
• Database of Abstracts of Reviews of
Effects (searched the Cochrane Library
2016, issue 1)
• Health Technology Assessment
Database (searched the Cochrane Library
2016, issue 1);
• ARIF: Aggressive Research
Intelligence Facility www.arif.bham.ac.uk
(searched 31 January 2016 for all dates)
Jan 2013: 3
Jan 2016: 0
9 ALOIS (see Appendix 3 for the Medline
strategy used to populate ALOIS)
(searched 15 January 2016)
Jan 2013: 22
Jan 2016: 0
TOTAL before de-duplication of search re-
sults
Apr 2011: 1361
Jul 2012: 215
Jan 2013: 107 (+3 from additional review sources)
Jan 2016: 149
TOTAL: 1835
TOTAL after de-duplification and first-as-
sess by the Trials Search Co-ordinator
TOTAL after assessment of 220 by author
team
220
83
Appendix 3. Search strategy (MEDLINE OvidSP) run for specialised register (ALOIS)
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MEDLINE in-process and other non-indexed citations and
MEDLINE OvidSP (1950 to present)
1. “word recall”.ti,ab.
2. “7-minute screen”.ti,ab.
3. “6 item cognitive impairment test”.ti,ab.
4. “6 CIT”.ti,ab.
5. “AB cognitive screen”.ti,ab.
6. “abbreviated mental test”.ti,ab.
7. “ADAS-cog”.ti,ab.
8. AD8.ti,ab.
9. “inform* interview”.ti,ab.
10. “animal fluency test”.ti,ab.
11. “brief alzheimer* screen”.ti,ab.
12. “brief cognitive scale”.ti,ab.
13. “clinical dementia rating scale”.ti,ab.
14. “clinical dementia test”.ti,ab.
15. “community screening interview for dementia”.ti,ab.
16. “cognitive abilities screening instrument”.ti,ab.
17. “cognitive assessment screening test”.ti,ab.
18. “cognitive capacity screening examination”.ti,ab.
19. “clock drawing test”.ti,ab.
20. “deterioration cognitive observee”.ti,ab.
21. “Dem Tect”.ti,ab.
22. “fuld object memory evaluation”.ti,ab.
23. “IQCODE”.ti,ab.
24. “mattis dementia rating scale”.ti,ab.
25. “memory impairment screen”.ti,ab.
26. “minnesota cognitive acuity screen”.ti,ab.
27. “mini-cog”.ti,ab.
28. “mini-mental state exam*”.ti,ab.
29. “mmse”.ti,ab.
30. “modified mini-mental state exam”.ti,ab.
31. “3MS”.ti,ab.
32. “neurobehavioural cognitive status exam*”.ti,ab.
33. “cognistat”.ti,ab.
34. “quick cognitive screening test”.ti,ab.
35. “QCST”.ti,ab.
36. “rapid dementia screening test”.ti,ab.
37. “RDST”.ti,ab.
38. “repeatable battery for the assessment of neuropsychological
status”.ti,ab
39. “RBANS”.ti,ab.
40. “rowland universal dementia assessment scale”.ti,ab.
41. “rudas”.ti,ab.
42. “self-administered gerocognitive exam*”.ti,ab.
43. (“self-administered” and “SAGE”).ti,ab.
44. “self-administered computerized screening test for dementia”.
ti,ab
45. “short and sweet screening instrument”.ti,ab.
46. “sassi”.ti,ab.
47. “short cognitive performance test”.ti,ab.
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48. “syndrome kurztest”.ti,ab.
49. “six item screener”.ti,ab.
50. “short memory questionnaire”.ti,ab.
51. (“short memory questionnaire” and “SMQ”).ti,ab.
52. “short orientation memory concentration test”.ti,ab.
53. “s-omc”.ti,ab.
54. “short blessed test”.ti,ab.
55. “short portable mental status questionnaire”.ti,ab.
56. “spmsq”.ti,ab.
57. “short test of mental status”.ti,ab.
58. “telephone interview of cognitive status modified”.ti,ab
59. “tics-m”.ti,ab.
60. “trail making test”.ti,ab.
61. “verbal fluency categories”.ti,ab.
62. “WORLD test”.ti,ab.
63. “general practitioner assessment of cognition”.ti,ab.
64. “GPCOG”.ti,ab.
65. “Hopkins verbal learning test”.ti,ab.
66. “HVLT”.ti,ab.
67. “time and change test”.ti,ab.
68. “modified world test”.ti,ab.
69. “symptoms of dementia screener”.ti,ab.
70. “dementia questionnaire”.ti,ab.
71. “7MS”.ti,ab.
72. (“concord informant dementia scale” or CIDS).ti,ab.
73. (SAPH or “dementia screening and perceived harm*”).ti,ab
74. or/1-73
75. exp Dementia/
76. Delirium, Dementia, Amnestic, Cognitive Disorders/
77. dement*.ti,ab.
78. alzheimer*.ti,ab.
79. AD.ti,ab.
80. (“lewy bod*” or DLB or LBD).ti,ab.
81. “cognit* impair*”.ti,ab.
82. (cognit* adj4 (disorder* or declin* or fail* or function*)).ti,ab
83. (memory adj3 (complain* or declin* or function*)).ti,ab.
84. or/75-83
85. exp “sensitivity and specificity”/
86. “reproducibility of results”/
87. (predict* adj3 (dement* or AD or alzheimer*)).ti,ab.
88. (identif* adj3 (dement* or AD or alzheimer*)).ti,ab.
89. (discriminat* adj3 (dement* or AD or alzheimer*)).ti,ab.
90. (distinguish* adj3 (dement* or AD or alzheimer*)).ti,ab.
91. (differenti* adj3 (dement* or AD or alzheimer*)).ti,ab.
92. diagnos*.ti.
93. di.fs.
94. sensitivit*.ab.
95. specificit*.ab.
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96. (ROC or “receiver operat*”).ab.
97. Area under curve/
98. (“Area under curve” or AUC).ab.
99. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.
100. sROC.ab.
101. accura*.ti,ab.
102. (likelihood adj3 (ratio* or function*)).ab.
103. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.
104. ((true or false) adj3 (positive* or negative*)).ab.
105. ((positive* or negative* or false or true) adj3 rate*).ti,ab
106. or/85-105
107. exp dementia/di
108. Cognition Disorders/di [Diagnosis]
109. Memory Disorders/di
110. or/107-109
111. *Neuropsychological Tests/
112. *Questionnaires/
113. Geriatric Assessment/mt
114. *Geriatric Assessment/
115. Neuropsychological Tests/mt, st
116. “neuropsychological test*”.ti,ab.
117. (neuropsychological adj (assess* or evaluat* or test*)).ti,ab
118. (neuropsychological adj (assess* or evaluat* or test* or exam*
or battery)).ti,ab
119. Self report/
120. self-assessment/ or diagnostic self evaluation/
121. Mass Screening/
122. early diagnosis/
123. or/111-122
124. 74 or 123
125. 110 and 124
126. 74 or 123
127. 84 and 106 and 126
128. 74 and 106
129. 125 or 127 or 128
130. (animals not (humans and animals)).sh.
131. 129 not 130
The concepts for this are:
A Specific neuropsychological tests (lines 1-73)
B General terms (both free text and MeSH) for tests/testing/
screening (lines 111-122)
COutcome: dementia diagnosis (unfocusedMeSHwith diagnos-
tic subheadings) (lines 107-109)
D Condition of interest: Dementia (general dementia terms both
free text and MeSH - exploded and unfocused) (75-83)
EMethodological filter: not used to limit all search (85-105)
The concept combinations are:
1. (A OR B) AND C
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2. (A OR B) AND D AND E
3. A AND E
Search strategy (MEDLINE OvidSP) run for specialised reg-
ister (ALOIS)
Search narrative: The search in Appendix 2 is largely based on
a single concept: the index test (IQCODE). This is a sensitive
approach to take. More complex and developed searches are run
each month for the dementia group
Every month the following strategy is run in MEDLINE (via
OvidSP). The results are screened based on a reading of title and
abstract. The full texts (where there is one) are then obtained and
a few key details about each study are extracted including Index
test/s and details of population and setting. For this review it was
expected that most studies would be identified through a search of
multiple sources based on one concept (the index test in question)
. However, we felt it was worth also searching ALOIS for any
studies which had evaluated the accuracy of IQCODE but had
not referred to it in the title or abstract of the reference
Appendix 4. Assessment of reporting quality - STARDdem checklist
SECTION AND TOPIC
TITLE/ABSTRACT
KEYWORDS
1 Identify the article as a study of diagnostic accuracy (recommend MeSH heading ’sensi-
tivity and specificity’)
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic accuracy or
comparing accuracy between tests or across participant groups
METHODS METHODS
Participants 3 The study population: The inclusion and exclusion criteria, setting and locations where
data were collected. See also item 4 on recruitment and item 5 on sampling
4 Participant recruitment: Was recruitment based on presenting symptoms, results from
previous tests, or the fact that the participants had received the index tests or the reference
standard? See also item 5 on sampling and item 16 on participant loss at each stage of
the study
5 Participant sampling: Was the study population a consecutive series of participants de-
fined by the selection criteria in item 3 and 4? If not, specify how participants were
further selected. See also item 4 on recruitment and item 16 on participant loss
6 Data collection: Was data collection planned before the index test and reference standard
were performed (prospective study) or after (retrospective study)?
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(Continued)
Test methods 7 The reference standard and its rationale.
8 Technical specifications of material and methods involved including how and when
measurements were taken, and/or cite references for index tests and reference standard.
See also item 10 concerning the person(s) executing the tests
9 Definition of and rationale for the units, cut-offs and/or categories of the results of the
index tests and the reference standard
10 The number, training and expertise of the persons executing and reading the index tests
and the reference standard. See also item 8
11 Whether or not the readers of the index tests and reference standard were blind (masked)
to the results of the other test and describe any other clinical information available to
the readers. See also item 7
Statistical methods 12 Methods for calculating or comparing measures of diagnostic accuracy, and the statistical
methods used to quantify uncertainty (e.g. 95% confidence intervals)
13 Methods for calculating test reproducibility, if done.
RESULTS RESULTS
Participants 14 When study was performed, including beginning and end dates of recruitment
15 Clinical and demographic characteristics of the study population (at least information
on age, sex, spectrum of presenting symptoms). See also item 18
16 The number of participants satisfying the criteria for inclusion who did or did not
undergo the index tests and/or the reference standard; describe why participants failed
to undergo either test (a flow diagram is strongly recommended). See also items 3 to 5
Test results 17 Time-interval between the index tests and the reference standard, and any treatment
administered in between
18 Distribution of severity of disease (define criteria) in those with the target condition;
other diagnoses in participants without the target condition
19 A cross tabulation of the results of the index tests (including indeterminate and missing
results) by the results of the reference standard; for continuous results, the distribution
of the test results by the results of the reference standard
20 Any adverse events from performing the index tests or the reference standard
Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% con-
fidence intervals). See also item 12
22 How indeterminate results, missing data and outliers of the index tests were handled
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(Continued)
23 Estimates of variability of diagnostic accuracy between subgroups of participants, readers
or centres, if done
24 Estimates of test reproducibility, if done. See also item 13
DISCUSSION DISCUSSION
25 Discuss the clinical applicability of the study findings.
Appendix 5. Assessment of methodological quality table QUADAS-2 tool
DOMAIN PATIENT
SELECTION
INDEX TEST REFERENCE
STANDARD
FLOW AND TIMING
Description Describe methods of pa-
tient selection: Describe
included patients (prior
testing, presentation, in-
tended use of index test
and setting):
Describe the index test
and how it was con-
ducted and interpreted:
Describe the reference
standard and how it
was conducted and in-
terpreted:
Describe any patients
who did not receive the
index test(s) and/or ref-
erence standard or who
were excluded from the
2 x 2 table (refer to flow
diagram): Describe the
time interval and any in-
terventions between in-
dex test(s) and reference
standard:
Signalling questions
(yes/no/unclear)
Was a consecutive or ran-
dom sample of patients
enrolled?
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Is the reference standard
likely to correctly classify
the target condition?
Was there an appropri-
ate interval between in-
dex test(s) and reference
standard?
Was a case-control de-
sign avoided?
If a threshold was used,
was it pre-specified?
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Did all patients receive a
reference standard?
Did the study avoid in-
appropriate exclusions?
Did all patients receive
the same reference stan-
dard?
Were all patients in-
cluded in the analysis?
Risk of bias: High/low/
unclear
Could the selection of
patients have introduced
bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
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(Continued)
Concerns regarding
applicability: High/low/
unclear
Are there concerns that
the included patients do
not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
Appendix 6. Anchoring statements for quality assessment of IQCODE diagnostic studies
We provide some core anchoring statements for quality assessment of diagnostic test accuracy reviews of IQCODE in dementia. These
statements are designed for use with the QUADAS-2 tool and were derived during a two-day, multidisciplinary focus group.
During the focus group and the piloting and validation of this guidance, it was clear that certain issues were key to assessing quality,
while other issues were important to record, but less important for assessing overall quality. To assist, we describe a system wherein
certain items can dominate. For these dominant items, if scored ’high risk’, then that section of the QUADAS-2 results table is likely
to be scored as high risk of bias, regardless of other scores. For example, in dementia diagnostic test accuracy studies, ensuring that
clinicians performing the dementia assessment are blinded to the results of index test is fundamental. If this blinding was not present,
then the item on the reference standard should be scored ’high risk’ of bias, regardless of the other contributory elements.
We have detailed how QUADAS2 has been operationlised for use with dementia reference standard studies below. In these descriptors,
dominant items are labelled as ’hIgh risk’.
In assessing individual items, the score of ’unclear’ should only be given if there is genuine uncertainty. In these situations, review
authors will contact the relevant study teams for additional information.
Anchoring statements to assist with assessment for risk of bias
Patient selection
1. Was a case-control or similar design avoided?
Designs similar to case control that may introduce bias are those designs where the study team deliberately increase or decrease the
proportion of patients with the target condition. For example, a population study may be enriched with extra dementia patients from
a secondary care setting. Such studies will be automatically labelled high risk of bias and will be assessed as a potential source of
heterogeneity.
High risk of bias (in fact, case-control studies will not be included in this review)
2. Was the sampling method appropriate?
Where sampling is used, the designs least likely to cause bias are consecutive sampling or random sampling. Sampling that is based on
volunteers or selecting participants from a clinic or research resource is prone to bias.
High risk of bias
3. Are exclusion criteria described and appropriate?
The study will be automatically graded as unclear if exclusions are not detailed (pending contact with study authors). Where exclusions
are detailed, the study will be graded as low risk if the review authors feel the exclusions are appropriate. Certain exclusions common
to many studies of dementia are: medical instability, terminal disease, alcohol or substance misuse, concomitant psychiatric diagnosis,
or other neurodegenerative conditions. For a community sample, we would expect relatively few exclusions.
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Post hoc exclusions will be labelled ’high risk’ of bias.
Low risk
Index test
4. Was IQCODE assessment performed without knowledge of clinical dementia diagnosis?
Terms such as ’blinded’ or ’independently and without knowledge of ’ are sufficient and full details of the blinding procedure are not
required. This item may be scored as low risk if explicitly described, or if there is a clear temporal pattern to the order of testing that
precludes the need for formal blinding i.e. all IQCODE assessments were performed before dementia assessment.
High risk
5. Were IQCODE thresholds pre-specified?
For scales, there is often a reference point (in units or categories) above which participants are classified as ’test positive’; this may be
referred to as threshold; clinical cut-off or dichotomisation point. A study is classified to be at high risk of bias if the authors define the
optimal cut-off post hoc, based on their own study data. Certain papers may use an alternative methodology for analysis that does not
use thresholds, and these papers should be classified as not applicable.
Low risk
6. Were sufficient data on IQCODE application given for the test to be repeated in an independent study?
Particular points of interest for IQCODE include method of administration (for example, self-completed questionnaire versus direct
questioning interview), nature of informant, and language of assessment. If a novel form of IQCODE is used, details of the scale
should be included, or a reference given to an appropriate descriptive text. Where IQCODE is used in a novel manner, for example, a
translated questionnaire, there should be evidence of validation.
Low risk
Reference standard
7. Is the assessment used for clinical diagnosis of dementia acceptable?
Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in DSM-IV and ICD-10.
Criteria specific to dementia subtypes include but are not limited to NINCDS-ADRDA criteria for Alzheimer’s dementia, McKeith
criteria for Lewy Body dementia, Lund criteria for frontotemporal dementias, and the NINDS-AIREN criteria for vascular dementia.
Where the criteria used for assessment are not familiar to the review authors and the Cochrane Dementia and Cognitive Improvement
group, this item should be classified as high risk of bias.
High risk
8. Was clinical assessment for dementia performed without knowledge of IQCODE?
Terms such as ’blinded’ or ’independent’ are sufficient, and full details of the blinding procedure are not required. This may be scored
as low risk if explicitly described, or if there is a clear temporal pattern to the order of testing i.e. all dementia assessments are performed
before IQCODE testing.
Informant rating scales and direct cognitive tests present certain problems. It is accepted that informant interview and cognitive testing
are usual components of clinical assessment for dementia, however, specific use of the scale under review in the clinical dementia
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assessment should be scored as high risk of bias. We have pre-specified that a dementia diagnosis that explicitly uses IQCDODE will
be classified as high risk of bias.
High risk
9. Were sufficient data on dementia assessment method given for the assessment to be repeated in an independent study?
The criteria used for clinical assessment are discussed in another item. Particular points of interest for dementia assessment include the
backgroundof the assessor, training/expertise of the assessor, and additional information available to inform the diagnosis (neuroimaging;
neuropsychological testing).
Low risk
Patient flow
10. Was there an appropriate interval between IQCODE and clinical dementia assessment.
For a study looking at delayed verification, there is no agreement on how long the interval should be between index test and first/last
assessment for dementia. An interval of less than six months is unlikely to be sufficient time for progression.
Low risk of bias
11. Did all patients get the same assessment for dementia regardless of IQCODE result?
There may be scenarios where only those patients who score ’test positive’ on IQCODE have a more detailed assessment. Where
dementia assessment (or other reference standard) differs between patients, this should be classified as high risk of bias.
High risk of bias
12. Were all patients who received IQCODE assessment included in the final analysis?
If dropouts, these should be accounted for; a maximum proportion of dropouts for this domain to remain at low risk of bias has been
specified as 20%.
Low risk of bias
13. Were missing IQCODE results or un-interpretable IQCODE results reported?
Where missing results are reported, and if there is substantial attrition (we have set an arbitrary value of 50% missing data), this should
be scored as high risk of bias.
Low risk of bias
Applicability
14. Were included patients representative of the general population of interest?
The included patients should match the intended population, as described in the review question. If not already specified in the review
inclusion criteria, setting will be particularly important - the review authors should consider the population in terms of symptoms, pre-
testing, and potential disease prevalence. Studies that use very selected patients or subgroups will be classified as poor applicability.
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15. Was IQCODE performed consistently and in a manner similar to its use in clinical practice?
IQCODE studies will be judged against the original description of its use.
16. Was clinical diagnosis of dementia (or other reference standard) made in a manner similar to current clinical practice?
For many reviews, inclusion criteria and assessment for risk of bias will already have assessed the dementia diagnosis. For certain reviews,
an applicability statement relating to the reference standard may not be applicable. There is the possibility that a form of dementia
assessment, although valid, may diagnose a far larger proportion of patients with disease than usual clinical practice. In this instance,
the item should be rated as poor applicability.
Appendix 7. STARDdem (reporting quality) results
Study ID STARDdem Item Assessment
Yes No
Caratozzolo 2014 3,4,6,9,14,15,16,17 1,2,5,7,8,10,11,12,13,18,19,20,21,22,23,24,25
Henon 2001 3,4,5,6,7,8,9,14,15,17 1,2,10,11,12,13,16,18,19,20,21,22,23,24,25
Krogseth 2011 3,4,6,7,8,9,10,14,15,16,17 1,2,5,11,12,13,18,19,20,21,22,23,24,25
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Quantitative analysis and planned sensitivity analyses were not possible due to the heterogeneity of the included studies.
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